Discovery of potent small molecule PROTACs targeting mutant EGFR

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Tony Mok, Yi‐Long Wu, Sumitra Thongprasert et al. · New England Journal of Medicine · 2009 · 8.2K citations · Full text

Medicine, Oncology, Pharmacology +13

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers

Helena A. Yu, Maria E. Arcila, Natasha Rekhtman et al. · Clinical Cancer Research · 2013 · 2.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation

Kathleen M. Sakamoto, Kyung B. Kim, Akiko Kumagai et al. · Proceedings of the National Academy of Sciences · 2001 · 2.5K citations · Full text

Life Sciences, Biochemistry, Molecular Biology +16

Phthalimide conjugation as a strategy for in vivo target protein degradation

Georg E. Winter, Dennis L. Buckley, Joshiawa Paulk et al. · Science · 2015 · 1.7K citations

Life Sciences, Molecular Biology, Oncology +14

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

Kenneth S. Thress, Cloud P. Paweletz, Enriqueta Felip et al. · Nature Medicine · 2015 · 1.5K citations · Full text

Medicine, Molecular Biology, Oncology +11